By Annalee Armstrong
Moderna is adding two more vaccine programs to its roster: a combination respiratory candidate and a shot targeting all four endemic human coronaviruses that cause the common cold.
read more
By Ben Adams
Initial uptake of Novavax’s newly launched COVID vaccine Nuvaxovid in Europe has been weak, but the company is still adamant the shot can reach the so-called vaccine hesitant across the continent—and hit its $4 billion sales projection.
read more
By Paige Minemyer
This year, Fierce Healthcare's #FierceMadness is back, and we want you to help us identify the industry's most influential person.
read more
By Andrea Park
In its first year-end financial report since going public on the London Stock Exchange in September, Oxford Nanopore Technologies had quite a big year to sum up.
read more
By Joseph Keenan
Takeda’s long slog to manufacture and relaunch its hypoparathyroidism drug Natpara got a lot tougher after the pharma giant announced it received a new complete response letter from the FDA.
read more
By Max Bayer
Aligos Therapeutics has ended development of its second med since January after four patients fell ill in a phase 1 trial testing its treatment for chronic hepatitis B, including one person who was hospitalized. As a result, the company is pivoting its pipeline to focus on small-molecule therapies.
read more
By Andrea Park
Eko’s AI has been proven in clinical studies to automatically detect both heart murmurs and afib with similar accuracy to trained professionals.
read more
By Paige Minemyer
Multiple national payers have released their annual proxy reports, offering a glimpse at what top industry execs earned in 2021.
read more
By Kevin Dunleavy
Pfizer has recalled six lots of its blood pressure drug Accuretic along with five lots of two of its generic hypertension treatments because of cancer-causing agents. The recalls come three weeks after Pfizer went through two rounds of recalls in Canada for two of its blood pressure medicines.
read more
By Annalee Armstrong
ORIC Pharmaceuticals is walking away from the lead program used to underpin its 2020 IPO after the cancer med did not demonstrate adequate clinical activity in several early-stage trials.
read more
By Robert King
CMMI Director Liz Fowler said more value-based care payment models are likely to have a requirement to create health equity plans that target underserved areas.
read more
By Conor Hale
The company’s Epione system helps plan and perform minimally invasive ablation surgery as an outpatient procedure, by deploying computer-guided needles through the skin to single out and destroy tumors.
read more
